跳至主要内容
临床试验/NCT01125995
NCT01125995已完成3 期

A Randomized Phase III Trial for Timing of Radiation in Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer

Samsung Medical Center3 个研究点 分布在 1 个国家目标入组 222 人开始时间: 2003年6月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
222
试验地点
3
主要终点
complete response rate

研究概览

简要总结

The purpose of the study is to evaluate the efficacy and toxicity of different timing of concurrent chemoradiation in the treatment of limited disease status Small-cell lung cancer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • histologically confirmed small-cell lung cancer
  • limited disease status
  • with evaluable disease
  • 18 years or older
  • ECOG performance status 0,1,2
  • expected survival time should be 12 weeks or longer
  • Adequate organ function as evidenced by the following; Absolute neutrophil count > 1.5 x 109/L; platelets > 100 x 109/L; total bilirubin ≤1.5 UNL; AST and/or ALT < 5 UNL; creatinine clearance ≥ 50mL/min
  • Written informed consent form

排除标准

  • Uncontrolled systemic illness such as DM, CHF, unstable angina, hypertension or arrhythmia
  • Patients with active infection requiring antibiotics
  • Pregnant or nursing women ( Women of reproductive potential have to agree to use an effective contraceptive method)
  • Prior history of malignancy within 5 years from study entry except for a adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, well-treated thyroid cancer
  • previous history of chemotherapy or radiotherapy

结局指标

主要结局

complete response rate

时间窗: 6 months

次要结局

  • overall survival(36 months)
  • objective response rate(6 months)
  • Progression-free survival(36 months)
  • toxicity by NCI common toxicity version 2.0(36 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Keunchil Park

Professor

Samsung Medical Center

研究点 (3)

Loading locations...

相似试验